ObalonBalloon Revenue and Competitors
Estimated Revenue & Valuation
- ObalonBalloon's estimated annual revenue is currently $5.8M per year.
- ObalonBalloon's estimated revenue per employee is $251,000
Employee Data
- ObalonBalloon has 23 Employees.
- ObalonBalloon grew their employee count by 5% last year.
ObalonBalloon Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is ObalonBalloon?
Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease.
keywords:N/A
N/A
Total Funding
23
Number of Employees
$5.8M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ObalonBalloon News
Silimed, Apollo Endosurgery, Medsil, Districlass Medical, Obalon Therapeutics, Allurion Technologies, Lexel, Helioscopie Medical Implants,...
The intragastric balloons types are categorized into single balloons, ... Fengh Medical, Medsil, Obalon Therapeutics, Phagia Technologies,...
... and regulatory requirements, manufacturing viability and quality system control necessary for reintroducing the Obalon Balloon System.
Other Companies in Carlsbad
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4M | 23 | 0% | N/A |
#2 | $4.3M | 23 | 5% | N/A |
#3 | $7.5M | 23 | -4% | N/A |
#4 | $2.3M | 23 | 10% | N/A |
#5 | N/A | 23 | -8% | N/A |